SID49677674

ID: ALA1471788

Chembl Id: CHEMBL1471788

PubChem CID: 4566836

Max Phase: Preclinical

Molecular Formula: C18H19F3N4S

Molecular Weight: 380.44

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1ccnc(NC(=S)N2CCN(c3cccc(C(F)(F)F)c3)CC2)c1

Standard InChI:  InChI=1S/C18H19F3N4S/c1-13-5-6-22-16(11-13)23-17(26)25-9-7-24(8-10-25)15-4-2-3-14(12-15)18(19,20)21/h2-6,11-12H,7-10H2,1H3,(H,22,23,26)

Standard InChI Key:  RBRSLSDXXMOOCE-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA1471788

   N-(4-methylpyridin-2-yl)-4-[3-(trifluoromethyl)phenyl]piperazine-1-carbothioamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 380.44

Molecular Weight (Monoisotopic): 380.1283

AlogP: 3.93

#Rotatable Bonds: 2

Polar Surface Area: 31.40

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 3.77

CX LogP: 4.72

CX LogD: 4.72

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.80

Np Likeness Score: -2.06

References

1. PubChem BioAssay data set, 

2. PubChem BioAssay data set, 

3. PubChem BioAssay data set, 

4. PubChem BioAssay data set, 

5. Foley TL, Rai G, Yasgar A, Daniel T, Baker HL, Attene-Ramos M, Kosa NM, Leister W, Burkart MD, Jadhav A, Simeonov A, Maloney DJ..  (2014)  4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.,  57  (3): [PMID:24450337] [10.1021/jm401752p]

6. Ravez S, Spillier Q, Marteau R, Feron O, Frédérick R..  (2017)  Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy.,  60  (4): [PMID:27959531] [10.1021/acs.jmedchem.6b01167]

7. Rohde JM, Brimacombe KR, Liu L, Pacold ME, Yasgar A, Cheff DM, Lee TD, Rai G, Baljinnyam B, Li Z, Simeonov A, Hall MD, Shen M, Sabatini DM, Boxer MB..  (2018)  Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.,  26  (8): [PMID:29555419] [10.1016/j.bmc.2018.02.016]

Source

Source(2):

• Scientific Literature
• PubChem BioAssays